Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Oragenics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
OGEN
NYSE American
2836
www.oragenics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Oragenics, Inc.
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
- Feb 11th, 2025 1:30 pm
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
- Feb 5th, 2025 1:15 pm
Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO
- Jan 21st, 2025 1:15 pm
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
- Dec 16th, 2024 1:09 pm
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
- Oct 18th, 2024 12:30 pm
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
- Oct 9th, 2024 11:30 am
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
- Oct 8th, 2024 12:45 pm
EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate
- Oct 8th, 2024 12:30 pm
Oragenics, Inc. Announces Closing of Public Offering
- Sep 5th, 2024 8:30 pm
Oragenics, Inc. Announces Pricing of Public Offering
- Sep 4th, 2024 12:36 pm
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
- Aug 21st, 2024 12:45 pm
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
- Aug 16th, 2024 8:30 pm
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
- Aug 14th, 2024 12:30 pm
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
- Aug 12th, 2024 12:30 pm
Oragenics: Q2 Earnings Snapshot
- Aug 9th, 2024 8:43 pm
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
- Aug 8th, 2024 12:45 pm
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase II Trials Underway
- Aug 8th, 2024 12:30 pm
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
- Jul 10th, 2024 12:00 pm
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
- Jun 27th, 2024 12:30 pm
Oragenics, Inc. Announces Proposed Public Offering
- Jun 24th, 2024 10:43 pm
Scroll